Hederagenin structure
|
Common Name | Hederagenin | ||
---|---|---|---|---|
CAS Number | 465-99-6 | Molecular Weight | 472.700 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 589.4±50.0 °C at 760 mmHg | |
Molecular Formula | C30H48O4 | Melting Point | 332 - 334ºC | |
MSDS | N/A | Flash Point | 324.3±26.6 °C |
Use of HederageninHederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κBHederagenin can Exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepression, anti-inflammation.[1]In vitro:1) Hederagenin can correct the imbalance of endothelial function by inhibiting the release of large amounts of iNOS and increasing eNOS contents and inhibits the IKKβ/NF-κB signaling pathway to reduce the release of IL-6, IFN-γ, TNF-α, and other inflammatory factors. [1]2) The EC50 of hederagenin is 39 ± 6 μM in A549 cancer cell line, but it's inactive for DLD-1 cells. [2]3) Hederagenin inhibited LPS-induced production of NO, PGE2and cytokines in cells.[3]4) Hederagenin had an anti-edema effect on the CA-induced mouse hind paw edema assay. [3]5) Hederagenin inhibited the CA-induced increase in skin thicknesses. [3]In vivo: The rats in the hederagenin group were administered hederagenin at 20 mg/kg/d via gavage.(More details please refer to the protocol below). In AS rat models induced by a high-lipid diet plus VD3, hederagenin can effectively reduce serum lipid, ALT, and AST levels, in addition to improving liver function, relieving high blood coagulation, and slowing blood flow and stasis by improving blood rheology. [1] |
Name | (4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid |
---|---|
Synonym | More Synonyms |
Description | Hederagenin is a triterpenoid saponin. It can inhibit LPS-stimulated expression of iNOS, COX-2, and NF-κBHederagenin can Exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antilipid peroxidation, antiplatelet aggregation, liver protection, antidepression, anti-inflammation.[1]In vitro:1) Hederagenin can correct the imbalance of endothelial function by inhibiting the release of large amounts of iNOS and increasing eNOS contents and inhibits the IKKβ/NF-κB signaling pathway to reduce the release of IL-6, IFN-γ, TNF-α, and other inflammatory factors. [1]2) The EC50 of hederagenin is 39 ± 6 μM in A549 cancer cell line, but it's inactive for DLD-1 cells. [2]3) Hederagenin inhibited LPS-induced production of NO, PGE2and cytokines in cells.[3]4) Hederagenin had an anti-edema effect on the CA-induced mouse hind paw edema assay. [3]5) Hederagenin inhibited the CA-induced increase in skin thicknesses. [3]In vivo: The rats in the hederagenin group were administered hederagenin at 20 mg/kg/d via gavage.(More details please refer to the protocol below). In AS rat models induced by a high-lipid diet plus VD3, hederagenin can effectively reduce serum lipid, ALT, and AST levels, in addition to improving liver function, relieving high blood coagulation, and slowing blood flow and stasis by improving blood rheology. [1] |
---|---|
Related Catalog | |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 589.4±50.0 °C at 760 mmHg |
Melting Point | 332 - 334ºC |
Molecular Formula | C30H48O4 |
Molecular Weight | 472.700 |
Flash Point | 324.3±26.6 °C |
Exact Mass | 472.355255 |
PSA | 77.76000 |
LogP | 7.41 |
Vapour Pressure | 0.0±3.8 mmHg at 25°C |
Index of Refraction | 1.569 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xi: Irritant; |
---|---|
Risk Phrases | R22 |
Safety Phrases | 22-45 |
Precursor 6 | |
---|---|
DownStream 9 | |
Olean-12-en-28-oic acid, 3,23-dihydroxy-, (3β)- |
(3beta,4alpha)-3,23-Dihydroxyolean-12-en-28-oic acid |
(4aS,6aS,6bR,8aR,9R,10S,12aR,12bR,14bS)-10-Hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-4a(2H)-picenecarboxylic acid |
Hederagenol |
Astrantiagenin E |
3,23-dihydroxyolean-12-en-28-oic acid |
Caulosapogenin |
Hederagenic acid |
Hederagenin |
EINECS 207-369-9 |
Melanthigenin |
3,23-Dihydroxyolean-12-en-28-acid |
(3b,4a)-3,23-Dihydroxyolean-12-en-28-oic Acid |
23-hydroxyoleanolic acid |
(3β)-3,23-Dihydroxyolean-12-en-28-oic acid |